Illumina (ILMN) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson (JNJ), and Novartis (NVS).
Under the collaboration, deCODE Genetics will process the samples from the UK Biobank using Illumina's Protein Prep solution, the company said.
The data generated from the study will be made available to the scientific research community, with the first tranche of the data expected to be released in H2.
Illumina Protein Prep has been in early access limited release and is expected to fully launch in H1.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.